prednisone + vincristine + cytarabine + methotrexate + etoposide + cyclophosphamide + doxorubicin

This is a multi-agent chemotherapy regimen composed of seven drugs: prednisone, vincristine, cytarabine, methotrexate, etoposide, cyclophosphamide, and doxorubicin. Each component has a distinct mechanism of action targeting rapidly dividing cancer cells through different pathways: - Prednisone is a synthetic glucocorticoid with lympholytic effects. - Vincristine is a vinca alkaloid that inhibits microtubule formation. - Cytarabine is an antimetabolite that inhibits DNA synthesis. - Methotrexate is an antimetabolite and antifolate agent inhibiting dihydrofolate reductase. - Etoposide inhibits topoisomerase II activity leading to DNA strand breaks. - Cyclophosphamide is an alkylating agent causing cross-linking of DNA strands. - Doxorubicin intercalates into DNA and inhibits topoisomerase II. This combination targets malignant hematologic cells at multiple points in the cell cycle and has been used in the treatment of aggressive leukemias (such as acute lymphoblastic leukemia) and lymphomas. The regimen aims to maximize anti-tumor efficacy by combining agents with non-overlapping toxicities and mechanisms[1][2][3][4].